<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="19" ids="28790">Serotonin</z:chebi> (5-hydroxytryptamine)(1B/1D) <z:chebi fb="4" ids="48705">agonists</z:chebi> are vasoconstrictors that can affect coronary and cerebral arteries </plain></SENT>
<SENT sid="1" pm="."><plain>Retrosternal chest, arm, and jaw pain following triptan use is generally attributed to "triptan sensations" and dismissed as noncardiac </plain></SENT>
<SENT sid="2" pm="."><plain>However, triptans narrow <z:mpath ids='MPATH_458'>normal</z:mpath> coronary arteries and occasionally trigger vasospasm </plain></SENT>
<SENT sid="3" pm="."><plain>They are contraindicated in atherosclerotic <z:e sem="disease" ids="C0042373" disease_type="Disease or Syndrome" abbrv="">vascular disease</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>Part 1 of this review examines the relationship of medications used in <z:hpo ids='HP_0002076'>migraine</z:hpo> with the likelihood of causing vasospasm or vasoconstriction, and the triggering of <z:hpo ids='HP_0011675'>cardiac arrhythmias</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>We report an illustrative case of polymorphic ventricular tachyarrhythmia, electrocardiogram changes consistent with <z:mp ids='MP_0004120'>cardiac ischemia</z:mp>, and acquired corrected QT interval lengthening following oral <z:chebi fb="0" ids="10650">sumatriptan</z:chebi> in a 53-year-old migraineur without risk factors for <z:hpo ids='HP_0001677'>coronary artery disease</z:hpo> (CAD) </plain></SENT>
<SENT sid="6" pm="."><plain>Extensive evaluation revealed insignificant single coronary vessel <z:hpo ids='HP_0002621'>atherosclerosis</z:hpo> and <z:e sem="disease" ids="C0010073" disease_type="Disease or Syndrome" abbrv="">coronary artery vasospasm</z:e> on ergonovine challenge </plain></SENT>
<SENT sid="7" pm="."><plain>The report highlights the hidden risk that may underlie a "triptan sensation" and the possible association of the vasospastic features of <z:e sem="disease" ids="C0034735" disease_type="Disease or Syndrome" abbrv="">Raynaud's phenomenon</z:e>, <z:hpo ids='HP_0002076'>migraine headaches</z:hpo>, and <z:e sem="disease" ids="C0010073" disease_type="Disease or Syndrome" abbrv="">coronary vasospasm</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>Part 1 discusses the risks for <z:hpo ids='HP_0001664'>Torsade de Pointes</z:hpo>, vasospasm, and <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>, with a review and discussion of case reports of triptan-associated cardiovascular events in migraineurs with and without CAD risk factors or documented CAD; of the epidemiology and studies of triptans, vasospasm, and <z:e sem="disease" ids="C1301700" disease_type="Disease or Syndrome" abbrv="">cardiovascular morbidity</z:e>; and of the relationship of variant <z:mp ids='MP_0006112'>angina</z:mp>, <z:hpo ids='HP_0002076'>migraine</z:hpo>, and vasospastic disease </plain></SENT>
<SENT sid="9" pm="."><plain>In the second part of this review, <z:hpo ids='HP_0002315'>headache</z:hpo> medications and their propensity for corrected QT prolongation will be summarized </plain></SENT>
</text></document>